CN106456752B - 癌症治疗剂的组合 - Google Patents

癌症治疗剂的组合 Download PDF

Info

Publication number
CN106456752B
CN106456752B CN201580018245.XA CN201580018245A CN106456752B CN 106456752 B CN106456752 B CN 106456752B CN 201580018245 A CN201580018245 A CN 201580018245A CN 106456752 B CN106456752 B CN 106456752B
Authority
CN
China
Prior art keywords
compound
her2
cancer
trastuzumab
lapatinib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580018245.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN106456752A (zh
Inventor
B.R.胡克
E.维尔克
A.马赫尔
R.卡莱塔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CN106456752A publication Critical patent/CN106456752A/zh
Application granted granted Critical
Publication of CN106456752B publication Critical patent/CN106456752B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201580018245.XA 2014-04-03 2015-03-09 癌症治疗剂的组合 Active CN106456752B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461974765P 2014-04-03 2014-04-03
US61/974765 2014-04-03
PCT/EP2015/000525 WO2015149909A1 (en) 2014-04-03 2015-03-09 Combinations of cancer therapeutics

Publications (2)

Publication Number Publication Date
CN106456752A CN106456752A (zh) 2017-02-22
CN106456752B true CN106456752B (zh) 2020-11-20

Family

ID=52692591

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580018245.XA Active CN106456752B (zh) 2014-04-03 2015-03-09 癌症治疗剂的组合

Country Status (15)

Country Link
US (1) US9980966B2 (cg-RX-API-DMAC7.html)
EP (1) EP3125935B1 (cg-RX-API-DMAC7.html)
JP (1) JP6629753B2 (cg-RX-API-DMAC7.html)
KR (1) KR102410696B1 (cg-RX-API-DMAC7.html)
CN (1) CN106456752B (cg-RX-API-DMAC7.html)
AR (1) AR099931A1 (cg-RX-API-DMAC7.html)
AU (1) AU2015240094B2 (cg-RX-API-DMAC7.html)
CA (1) CA2944573C (cg-RX-API-DMAC7.html)
ES (1) ES2768900T3 (cg-RX-API-DMAC7.html)
IL (1) IL248126A0 (cg-RX-API-DMAC7.html)
MX (1) MX370540B (cg-RX-API-DMAC7.html)
NZ (1) NZ725361A (cg-RX-API-DMAC7.html)
RU (1) RU2733401C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201608189WA (cg-RX-API-DMAC7.html)
WO (1) WO2015149909A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230110296A (ko) * 2020-11-16 2023-07-21 메르크 파텐트 게엠베하 암 치료를 위한 키나제 억제제 조합
WO2025168601A1 (en) * 2024-02-05 2025-08-14 Evexta Bio Quinazoline carboxamide azetidine compounds for use in treating hormone dependent diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101300029A (zh) * 2005-11-04 2008-11-05 惠氏公司 mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
CN103228649A (zh) * 2010-11-24 2013-07-31 默克专利股份公司 喹唑啉甲酰胺氮杂环丁烷

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
JP2006522124A (ja) 2003-04-03 2006-09-28 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼのインヒビターとして有用な組成物
US7189729B2 (en) 2003-09-30 2007-03-13 Irm Llc Methods and compositions as protein kinase inhibitors
US7816353B2 (en) 2003-10-24 2010-10-19 Exelixis, Inc. P70S6 kinase modulators and method of use
ATE400573T1 (de) 2003-11-21 2008-07-15 Novartis Pharma Gmbh 1h-imidazochinolinderivate als proteinkinaseinhibitoren
JP2007513962A (ja) 2003-12-09 2007-05-31 アメリカ合衆国 免疫応答を抑制するため、または増殖性障害を治療するための方法
JP5213229B2 (ja) 2004-04-23 2013-06-19 エグゼリクシス， インコーポレイテッド キナーゼ調節因子および使用方法
JP5274842B2 (ja) 2004-12-28 2013-08-28 エグゼリクシス， インコーポレイテッド 免疫疾患、炎症疾患および増殖疾患の処置のためのセリン−スレオニンキナーゼモジュレーター（ｐ７０Ｓ６Ｋ、Ａｋｔ−１およびＡｋｔ−２）としての［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジンまたは［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジン化合物
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
US20060188498A1 (en) * 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
WO2006136821A1 (en) 2005-06-22 2006-12-28 Astex Therapeutics Limited Pharmaceutical compounds
UA99284C2 (ru) 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ
UY31800A (es) 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
UA107188C2 (uk) 2009-02-11 2014-12-10 Карбоксамідні похідні хіназолінів або хінолінів та фармацевтична композиція на їх основі
NZ603570A (en) 2010-05-20 2014-12-24 Ablynx Nv Biological materials related to her3
UA110113C2 (xx) 2010-07-29 2015-11-25 Біциклічні азагетероциклічні карбоксаміди
HK1218756A1 (zh) 2013-03-11 2017-03-10 默克专利有限公司 用作激酶活性调节剂的6-[4-(1h-咪唑-2-基)哌啶-1-基]嘧啶-4-胺衍生物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101300029A (zh) * 2005-11-04 2008-11-05 惠氏公司 mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
CN103228649A (zh) * 2010-11-24 2013-07-31 默克专利股份公司 喹唑啉甲酰胺氮杂环丁烷

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Celina García-García等.Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy.《Clinical Cancer Research》.2012,第18卷(第9期), *
Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy;Celina García-García等;《Clinical Cancer Research》;20120308;第18卷(第9期);第2604页左栏末段和右栏第2-3段 *
mTOR抑制剂依维莫司在乳腺癌治疗中的研究进展;曾敏等;《癌症进展》;20120930;第10卷(第5期);第475页左栏第2-3段 *

Also Published As

Publication number Publication date
KR20160133005A (ko) 2016-11-21
CN106456752A (zh) 2017-02-22
BR112016020135A2 (pt) 2017-08-15
RU2733401C2 (ru) 2020-10-01
JP2017509683A (ja) 2017-04-06
ES2768900T3 (es) 2020-06-24
US20170100402A1 (en) 2017-04-13
CA2944573C (en) 2022-10-25
EP3125935A1 (en) 2017-02-08
MX370540B (es) 2019-12-17
IL248126A0 (en) 2016-11-30
RU2016143153A (ru) 2018-05-04
KR102410696B1 (ko) 2022-06-17
AR099931A1 (es) 2016-08-31
WO2015149909A1 (en) 2015-10-08
AU2015240094B2 (en) 2020-07-30
AU2015240094A1 (en) 2016-11-17
RU2016143153A3 (cg-RX-API-DMAC7.html) 2018-10-17
EP3125935B1 (en) 2019-10-23
CA2944573A1 (en) 2015-10-08
SG11201608189WA (en) 2016-10-28
NZ725361A (en) 2022-09-30
US9980966B2 (en) 2018-05-29
MX2016012825A (es) 2017-01-05
BR112016020135A8 (pt) 2021-07-06
JP6629753B2 (ja) 2020-01-15

Similar Documents

Publication Publication Date Title
AU2019416117B2 (en) CSF1R inhibitors for use in treating cancer
CN105873440B (zh) 抑制tie2激酶的组合物在制备治疗癌症的药物中的用途
CN109310677A (zh) 通过联合施用ccr1拮抗剂与pd-1抑制剂或pd-l1拮抗剂降低肿瘤负荷
CN107864625A (zh) 含有取代的2,3‑二氢咪唑并[1,2‑c]喹唑啉的组合产品
AU2013234767B2 (en) Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with other anti-tumor compounds
AU2019206652B2 (en) Deuterated compounds, compositions, and methods for treating cancers associated with ETBR activation
KR20230113594A (ko) Pik3ca 돌연변이 암을 치료하기 위한 병용 요법
CA3239205A1 (en) Combination therapy comprising an fgfr inhibitor and a kras inhibitor
CN106456752B (zh) 癌症治疗剂的组合
US11992478B2 (en) Methods of using androgen receptor inhibitors as cancer therapeutics
WO2018213770A1 (en) Therapeutic methods
US11684672B2 (en) Combinations of copanlisib with anti-PD-1 antibody
BR112016020135B1 (pt) Mistura de compostos, seus usos, composição farmacêutica, e conjunto (kit)
US20240382495A1 (en) Combinations of copanlisib with anti-pd-1 antibody
US20240024324A1 (en) Kinase inhibitor combinations for cancer treatment
NZ750260A (en) Antitumor agent and antitumor effect enhancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant